How much does Stem Cell Treatment for Multiple Sclerosis (MS) cost?
At Stem Cell Mexico, stem cell treatment for multiple sclerosis (MS) typically costs between $7,000 and $9,500 USD.

The final price depends on the type of MS you have, your level of disability, the number of cells recommended, the route of administration, whether more than one session is planned, any special accommodations you need during your stay and how long you require medical observation. Your complete cost is confirmed in writing after a medical evaluation and before any deposit, and only the items listed in your quote are included.
"Stem cell treatment for MS" can refer to very different procedures, from an intensive immune "reset" performed in transplant centers to outpatient infusions of mesenchymal stromal cells. Understanding that difference is the most important step in comparing prices and expectations. This guide explains it clearly.
Two very different "stem cell" treatments for MS
Autologous hematopoietic stem cell transplantation (aHSCT)
This is a hospital-based procedure in which a person's own blood-forming stem cells are collected, intensive chemotherapy is used to reset immune activity, and the stored cells are reinfused. The goal is to control the immune attack that drives highly active MS. The MS International Federation (MSIF) describes aHSCT as an intensive treatment that requires careful patient selection and a specialized transplant setting. It has a very different purpose, recovery process and risk profile from outpatient mesenchymal stromal cell therapy.
Mesenchymal stromal cell (MSC) therapy
MSCs, such as those derived from umbilical cord tissue, do not rebuild the immune system. They are studied because they can modulate immune activity, reduce inflammation and release neuroprotective signals. They are given without chemotherapy, usually by intravenous infusion, and patients can typically return home within days. This is the approach used at Stem Cell Mexico.
Because these are completely different treatments, their prices, risks and evidence should never be compared directly.
What the price usually includes
Each quote is personalized, but generally includes:
- Consultation with the doctor and stem cell specialist, reviewing your MS type, MRI reports, relapse history, disability level (often measured with the EDSS scale) and current disease-modifying therapy.
- Pre-treatment laboratory testing: blood count, metabolic panel, urinalysis and tumor markers.
- Allogeneic MSCs derived from donated umbilical cord tissue, prepared for your scheduled date.
- Administration according to your plan under medical supervision.
- Medical observation with nursing care, ground transportation between the San Diego airport area and the clinic, patient coordination and follow-up.
Flights, extra hotel nights and companion lodging are usually separate unless listed.
Why the price varies within the range
Type of MS
- Relapsing-remitting MS (RRMS): episodes of new or worsening symptoms followed by recovery.
- Secondary progressive MS (SPMS): gradual worsening after an initial relapsing phase.
- Primary progressive MS (PPMS): steady progression from the start.
Inflammatory activity is highest in RRMS, while progressive forms involve more neurodegeneration. The type of MS influences goals and protocol.
Disability and support needs
Patients who use mobility aids, need help with transfers or have bladder management needs may require additional support, accessible transportation or extra observation.
Dose and sessions
Higher doses or a plan that anticipates repeated infusions increase the total. Dose is based on body weight, health status and goals.
What MS is and how it is treated today
Multiple sclerosis is a chronic immune-mediated disease in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. This disrupts nerve signals and can cause fatigue, numbness, weakness, vision problems, balance difficulties, bladder symptoms and cognitive changes.
Over the past two decades, treatment has improved dramatically. Disease-modifying therapies (DMTs), including high-efficacy options such as anti-CD20 antibodies and natalizumab, reduce relapses and new MRI lesions and slow disability in many patients. Rehabilitation, symptom management and healthy lifestyle habits are also essential. Any regenerative therapy should be considered alongside this care, with your neurologist informed. DMTs should not be stopped without specialist guidance.
How MSC therapy is thought to work in MS
Mesenchymal stromal cells may help in several ways:
- Immunomodulation: shifting immune cells away from an inflammatory, myelin-attacking state toward a more regulated balance.
- Reducing inflammation in the central nervous system.
- Neuroprotection: releasing trophic factors that may protect nerve fibers and support the cells that produce myelin.
- Supporting repair processes, a key unmet need in progressive MS.
These mechanisms are well documented in laboratory and animal studies. The open question is how much they translate into measurable clinical benefit in people.
What the evidence says
aHSCT has important evidence in selected patients: A randomized clinical trial published in JAMA in 2019 (Burt and colleagues) compared nonmyeloablative aHSCT with continued DMTs in 110 people with highly active relapsing-remitting MS and found lower disease progression in the transplant group during follow-up. This evidence is important because it shows how different stem-cell strategies can target different goals. aHSCT aims to reset immune activity; outpatient MSC therapy aims to modulate inflammation and support the tissue environment without chemotherapy.
MSC therapy shows safety and mixed efficacy signals: The MESEMS trial, an international randomized, double-blind, placebo-controlled crossover study published in The Lancet Neurology in 2021, tested IV autologous bone-marrow MSCs in people with active MS. The infusions were safe and well tolerated. Other studies, including some using intrathecal delivery in progressive MS, have reported encouraging changes in disability measures.
What this means for you: Disease-modifying therapy remains central to controlling MS activity. MSC therapy can be considered as a lower-intensity regenerative option with a favorable safety profile for selected patients who are looking for additional support for inflammation, function and quality of life, particularly when progressive symptoms remain despite ongoing neurological care. The medical evaluation helps define where it fits in your overall plan.
Regulatory context
No MSC product is approved by the FDA or the European Medicines Agency for MS. In Mexico, cell therapies are regulated by COFEPRIS and must come from licensed laboratories.
How MS activity and disability are measured
Two kinds of information guide any MS treatment decision. MRI shows inflammatory activity: new or enlarging lesions and lesions that light up with contrast (gadolinium) indicate active inflammation. Clinical scales describe how the disease affects daily life. The Expanded Disability Status Scale (EDSS) runs from 0 (normal neurological exam) to 10, with walking ability becoming central from about 4.0 upward; the timed 25-foot walk, the nine-hole peg test for hand function and fatigue questionnaires add detail. Having recent MRI reports and these measurements before treatment gives you and your doctors a clear baseline, which is the only reliable way to judge whether anything changes afterward.
Who may be a candidate
Evaluation considers:
- Confirmed MS diagnosis, type and current disease activity on MRI.
- Disability level, symptoms and goals.
- Current DMT and recent relapses (a recent relapse may mean waiting until you are stable).
- General health, no active infection and no cancer history within the past five years.
- Access to ongoing neurological care and rehabilitation.
What results patients commonly ask about
Will it stop my MS? MSC therapy is not designed to replace disease-modifying treatment, which remains the way to control MS activity. Goals usually focus on symptoms such as fatigue, mobility and quality of life, measured over time.
When might I notice changes? If they occur, they are generally evaluated over three to six months.
How do we measure benefit? With EDSS scores, timed walking tests, fatigue scales, MRI follow-up and your neurologist's assessment.
What can affect outcomes
- Type of MS, disease duration and disability level.
- Ongoing inflammatory activity.
- Exercise, rehabilitation, vitamin D status, sleep and smoking.
- Management of other conditions such as depression or bladder problems.
Preparing for treatment
Share recent MRI reports, neurology notes and a full medication list, including your DMT and when you last received it. Some DMTs affect the immune system for months, and your doctor will consider timing. Let us know about heat sensitivity, fatigue patterns and mobility needs so travel days can be planned comfortably.
Risks and limitations
IV MSC infusions have generally been well tolerated, with possible temporary fever, headache or fatigue, and rare allergic or thrombotic events. aHSCT, by contrast, carries serious risks related to chemotherapy and immune suppression. Results vary between patients.
Questions to ask during your evaluation
- Is this MSC therapy or HSCT, and what does that mean for risks and goals?
- What dose and route do you recommend for my type of MS?
- Should I continue my DMT, and how will timing be coordinated?
- How will results be measured?
- What exactly is included in my quote?
Bottom line
MSC treatment for multiple sclerosis at Stem Cell Mexico typically ranges from $7,000 to $9,500 USD. It is a lower-intensity option distinct from hematopoietic stem cell transplantation, with a favorable safety record. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your type of MS, goals and medical history, and gives you a written quote before you decide.
References
- MS International Federation (MSIF): Stem cell therapy for MS (opens in a new tab)
- Burt RK et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA, 2019 (opens in a new tab)
- Uccelli A et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet Neurology, 2021 (opens in a new tab)
